EEF2K (eukaryotic elongation factor 2 kinase)

Show simple item record Ozpolat, Bulent - Ozkayar, Ozgur - 2018-03-13T11:38:55Z 2018-03-13T11:38:55Z 2016 -
dc.identifier.citation Bulent, Ozpolat ; Ozgur, Ozkayar. EEF2K (eukaryotic elongation factor 2 kinase). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2016, 9, p. 478-480 -
dc.identifier.issn 1768-3262 -
dc.description.abstract Eukaryotic elongation factor 2 kinase (eEF-2K) (also known as Calmodulin (CaM)-dependent elongation factor 2 kinase,CaMKIII) is an unusual calcium/calmodulin (Ca2+/CaM)-dependent Threonin kinase that controls the rate of the elongation phase of protein synthesis through phosphorylating elongation factor 2 (eEF2) (Nairn et al., 1985; Ryazanov 1987; Mitsui et al., 1993; Redpath et al., 1993). Phosphorylation of eEF2 on Thr-56 disrupts the interaction between eEF-2 and the ribosome, leading to reduced protein synthesis. eEF-2K is regulated by phosphorylation by multiple signaling pathways and kinases at 11 different phosphorylation sides (Ryazanov et al., 1988; Carlberg et al., 1990; Abramczyk et al., 2011; Browne et al., 2004; Marshall et al., 2012; Chafouleas et al., 1981; Bowden et al., 2013). Hypoxia, nutrient deprivation and metabolic stress are all known to stimulate eEF-2K through activation of AMPK (Chafouleas et al., 1981).The activity of eEF-2K is increased in rapidly proliferating malignant cells and in cancer specimens, but is absent in normal adjacent tissues (Ashour et al., 2014b). eEF-2K promotes cell proliferation, invasion and tumorigenesis of some cancers. eEF-2K expression (mRNA) correlates with poor patient survival and prognosis (outcome) in some solid tumors, including breast , pancreatic cancer and glioblastoma (Meric-Bernstam et al., 2012). The activity of this kinase is increased in many cancers and may be a potential therapeutic target in some cancer en
dc.language.iso en -
dc.publisher ARMGHM - Atlas Génétique des Cancers -
dc.relation Atlas of Genetics and Cytogenetics in Oncology and Haematology ; -
dc.relation.ispartofseries Atlas of Genetics and Cytogenetics in Oncology and Haematology en
dc.rights Open access resource - terms and conditions : -
dc.subject elongation en
dc.subject protein translation en
dc.subject proliferation en
dc.subject invasion en
dc.subject prognosis en
dc.subject survival en
dc.subject cancer en
dc.subject.classification Genes Section en
dc.subject.mesh Acetophenones/administration & dosage en
dc.subject.mesh Benzopyrans/administration & dosage en
dc.subject.mesh Cell Line, Tumor en
dc.subject.mesh Elongation Factor 2 Kinase/*genetics/metabolism en
dc.subject.mesh Epithelial-Mesenchymal Transition/genetics en
dc.subject.mesh GTP-Binding Proteins en
dc.subject.mesh Gene Expression Regulation, Neoplastic/drug effects en
dc.subject.mesh Humans en
dc.subject.mesh Integrin beta1/*biosynthesis/genetics en
dc.subject.mesh Neoplasm Invasiveness/genetics en
dc.subject.mesh Pancreatic Neoplasms/*genetics/pathology en
dc.subject.mesh RNA, Small Interfering en
dc.subject.mesh Receptors, Urokinase Plasminogen Activator/*biosynthesis/genetics en
dc.subject.mesh Signal Transduction/genetics en
dc.subject.mesh Transglutaminases/*biosynthesis en
dc.subject.mesh src-Family Kinases/biosynthesis/genetics en
dc.subject.mesh Animals en
dc.subject.mesh Blood Pressure/drug effects/physiology en
dc.subject.mesh Cells, Cultured en
dc.subject.mesh Disease Models, Animal en
dc.subject.mesh Elongation Factor 2 Kinase/antagonists & inhibitors/drug effects/*physiology en
dc.title EEF2K (eukaryotic elongation factor 2 kinase) en
dc.type Article -
dc.contributor.affiliation University of Texas-Houston-MD Anderson Cancer Center, Department of Experimental Therapeutics, 1515 Holcombe Boulevard, Unit 422, Houston, TX7730 -

Files in this item

PDF 01-2016-EEF2KID40411ch16p12.pdf 186.7Kb

This item appears in the following Collection(s)

Show simple item record

Advanced Search